Nanomedicine holds strong potential to transform gastric cancer therapy through selective, target-driven interventions. However, successful translation requires better molecular stratification, deeper insight into nano - bio interactions, standardized toxicity evaluation, and scalable manufacturing. Integrating genomics, biomarkers, and AI-driven design will be crucial for developing nanotherapeutics that address specific molecular vulnerabilities in gastric cancer.
Saeed et al. (Wed,) studied this question.